Search Results

Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoff

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that Vantive will be the name of the company’s proposed spinoff of its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier, subject to satisfaction of customary conditions. 

Baxter Publishes Annual Corporate Responsibility Report, Reinforcing Longstanding Commitment to Making a Meaningful Difference

Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its 2022 Corporate Responsibility Report.

Baxter Names Chris Toth CEO of Proposed Kidney Care Spinoff

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has selected Chris Toth to be chief executive officer (CEO) of the company’s planned spinoff of its Renal Care and Acute Therapies businesses. Until the spinoff, which remains subject to satisfaction of customary conditions and is currently expected to occur by July 2024 or earlier, Mr.

Baxter Reports First-Quarter 2023 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2023.

Baxter Launches Zosyn Premix In US

Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.

Turn Insights Into Action With Connected Medical Devices

As we strive to build digital health solutions that help streamline hospital operations and personalize patient care, we are collaborating with Amazon Web Services (AWS) to deliver actionable insights that can help clinicians make informed decisions.

Baxter Reports Fourth-Quarter and Full-Year 2022 Results

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023. 

Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders

Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, accelerate innovation and create additional value for all stakeholders.

Baxter Highlights New Home Dialysis and HDx Therapy Data in 14 Clinical Presentations at Kidney Week 2022

Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, advanced scientific exchange with 14 new data presentations about the role innovation plays in increasing access to and quality of home dialysis and expanded hemodialysis (HDx) care at Kidney Week 2022, Nov. 3-6, Orlando, Florida. Key data highlighted include:

Activating Our Passion to Increase Kidney Care Access

We spoke with Peter Rutherford, MB BS, PhD, FRCP, vice president of Worldwide Medical Affairs for our Renal Care business, about his experience as a practicing nephrologist and his quest to improve global access to kidney care and patient outcomes.